27 patents
Utility
GIP agonist compounds and methods
14 Nov 23
The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
Filed: 2 Apr 21
Utility
Glucagon analogues
24 Oct 23
The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia.
Ditte Riber, Lise Giehm
Filed: 11 Sep 19
Utility
Kv1.3 blockers
10 Oct 23
The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
Filed: 24 Feb 22
Utility
Cyclic peptides multimers targeting α-4-β-7 integrin
1 Aug 23
Mohammed Monzur Morshed, Sai Kumar Chakka, Jennifer L. Hickey, Manuel Perez Vazquez, Andrew Roughton, Adam Paul Kafal, Narendrakumar B. Patel
Filed: 19 Apr 21
Utility
Acylated GLP-1/GLP-2 dual agonists
26 Jul 22
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne Due Larsen, Jonathan Griffin, Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 6 Apr 20
Utility
Amylin analogues
12 Jul 22
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes.
Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
Filed: 25 Oct 19
Utility
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
10 May 22
The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
Bjarne Due Larsen, Ulrik Mouritzen, Dongjoon Kim, Sayon Roy
Filed: 4 May 18
Utility
KV1.3 blockers
5 Apr 22
The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
Filed: 23 Jun 21
Utility
Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
29 Mar 22
There is described herein antagonists of α4β7 integrin, and more particularly cyclic peptide antagonists, such as compounds of formula (I).
Manuel Perez Vazquez, M. Monzur Morshed, Adam Paul Kafal, Jennifer L. Hickey, Andrew Roughton
Filed: 10 May 18
Utility
Time delay mechanism for a hydraulic drug delivery device
22 Mar 22
A medicament delivery device may comprise a medicament chamber configured to hold a medicament, a plunger configured to move relative to the medicament chamber to expel the medicament from the medicament chamber, a pin configured to move from a first pin position wherein the pin prevents movement of the plunger to a second pin position wherein the pin allows movement of the plunger, an actuation assembly configured to move the pin from the first pin position to the second pin position, and a needle coupled to the medicament chamber.
Christopher Gregory, Geoffrey Jenkins
Filed: 20 Jun 18
Utility
Acylated glucagon analogue
15 Mar 22
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Leo Thomas
Filed: 13 May 19
Utility
GLP-1/GLP-2 dual agonists
28 Sep 21
The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors.
Bjarne Due Larsen, Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 11 Dec 17
Utility
Cyclic peptides multimers targeting alpha-4-beta-7 integrin
7 Sep 21
There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).
Mohammed Monzur Morshed, Sai Kumar Chakka, Jennifer L. Hickey, Manuel Perez Vazquez, Andrew Roughton, Adam Paul Kafal, Narendrakumar B. Patel
Filed: 10 Nov 17
Utility
Glucagon-GLP-1-GIP triple agonist compounds
7 Sep 21
The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
Filed: 4 Oct 18
Utility
Acylated glucagon analogues
17 Aug 21
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
Filed: 12 Sep 19
Utility
Cyclic peptides targeting alpha-4-beta-7 integrin
27 Jul 21
Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
Filed: 14 Nov 16
Utility
Fragment synthesis of substituted cyclic peptides
29 Jun 21
Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
Filed: 14 Nov 16
Utility
Glucagon analogues and methods of use
15 Jun 21
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders.
Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht
Filed: 4 May 18
Utility
GIP-GLP-1 dual agonist compounds and methods
18 May 21
The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
Filed: 27 Aug 18
Utility
GIP agonist compounds and methods
11 May 21
The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
Filed: 21 Feb 19